Journal
NATURE BIOTECHNOLOGY
Volume 33, Issue 6, Pages 661-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3235
Keywords
-
Categories
Funding
- National Institutes of Health [NIH CA174793]
- Burroughs-Wellcome Fund Career Award for Medical Scientists
- Alex's Lemonade Stand Foundation 'A' Award
- National Cancer Institute Cancer Center Support Grant Development Funds [CA45508]
- Simons Center for Quantitative Biology at Cold Spring Harbor Laboratory
Ask authors/readers for more resources
CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-Cas9-induced mutations to the 5' exons of candidate genes(1-5), but this approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR-Cas9 mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We also show that the magnitude of negative selection can be used to infer the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available